Enliven Therapeutics, Inc. ELVN 深 滬
等待開盤 01-12 09:30:00 美东时间
26.00
+2.750
+11.83%
華盛通- 最 高29.98
- 今 開23.58
- 成交量 578.65万股
- 最 低 23.2724
- 昨 收 23.25
- 總市值 15.43亿
- 52周最高 29.98
- 市盈率 靜 --
- 換手率 9.75%
- 52周最低 13.30
- 委 比 -96.26%
- 總股本 5934.73万
- 歷史最高 250.84
- 量 比 2.47
- 振 幅 28.85%
- 歷史最低 3.896
- 每 手 1
- 風險率 1.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%
ANPA周涨近300%，公司获私募大额股份认购；脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%，治疗银屑病新药临床成功>>
01-10 06:27
美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
Enliven Therapeutics Announces Initial Data From Ongoing Phase 1b ENABLE Clinical Trial Evaluating ELVN-001 In Patients With CML That Is Relapsed, Refractory Or Intolerant To Available TKIs
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohortsELVN-001 continues to demonstrate a favorable safety and
01-08 22:08
美股周涨跌榜 | “减肥神药”临床数据引爆！WaVe生命科学周涨121%；太空概念股Planet Labs周涨42.8%
“减肥神药”临床数据引爆！WaVe生命科学周涨121%；福尼克斯周内飙升50%，创历史新高；SpaceX上市传闻引爆市场，太空概念股Planet Labs周涨42.8%>>
2025-12-13 10:07
Enliven Therapeutics Appoints Rick Fair As CEO And Member Of Board Of Directors, Effective Immediately
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive OfficerCo-Founder Sam Kintz will assume a new position as Head of PipelineBOULDER,
2025-12-11 22:04
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.
2025-12-09 20:51
Enliven's ELVN-001 Shows Anti-CML Activity In Patients With Atypical Fusion Transcripts; Will Present Data From The Ongoing ENABLE Phase 1a/1b Clinical Trial Of ELVN-001 On A Subset Of Chronic Myeloid LeukemiaPatients At The ASH 2025 Annual Meeting
ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcriptsGrowing unmet need for patients with atypical transcript e13a3, which is resistant to TKIs targeting the
2025-11-03 22:09
Enliven Therapeutics Q2 EPS $(0.49) Beats $(0.54) Estimate
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.54) by 9.26 percent. This is a 19.51 percent decrease over losses of $(0.41) per share
2025-08-14 04:25
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
2025-07-18 21:30
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
2025-07-03 11:01
